Sector News

Lilly hands its oncology baton to R&D executive Anne White

September 3, 2018
Life sciences

With oncology head Sue Mahony retiring today, Eli Lilly has her replacement ready to step in.

The company has promoted Anne White, currently VP of portfolio management for Lilly’s Chorus and next gen R&D units, to take on the role of SVP and president of Lilly Oncology, a unit Lilly says will be key to its growth future. She’ll step in as of this Saturday, reporting directly to Lilly CEO David Ricks.

White will have big shoes to fill, as Mahony—who said in May that she’d depart—saw the company through some key changes in her 18 years with the drugmaker. She spearheaded the launch of Verzenio, Lilly’s answer to Pfizer breast cancer blockbuster Ibrance, last year, and she managed the integration of Lilly’s 2008 ImClone acquisition as well.

White, though, brings more than 25 years of biopharma experience of her own to the table. Before landing in her current position, she held various jobs both inside and outside of Lilly, including COO of oncology. Plus, White’s R&D background will likely come in handy as Lilly looks to advance a number of oncology pipeline candidates, including next-gen immuno-oncology therapies.

“Her experience leading significant change transformation within the company will be incredibly valuable as we look toward the future,” Ricks said in a statement, adding that she brings “a wealth of … expertise and leadership to our executive team.”

White will draw on that experience to keep the Verzenio launch rolling and pump up other recent launches, too. Lilly is counting on drugs Cyramza and Lartruvo, in addition to the breast-cancer fighter, to help it meet 2018 sales forecasts of $23 billion to $23.5 billion.

Meanwhile, it’s been a big week for commercial appointments around the industry. Earlier in the week, Gilead poached Laura Hamill from Amgen to take its top commercial post, while Bristol-Myers Squibb promoted Christopher Boerner to commercial head to replace Murdo Gordon, who left for Amgen.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend